429 related articles for article (PubMed ID: 17155930)
1. New mechanisms and targets in the treatment of bone fragility.
Martin TJ; Seeman E
Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
[TBL] [Abstract][Full Text] [Related]
2. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
3. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
Seeman E
Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
[TBL] [Abstract][Full Text] [Related]
4. Current and investigational approaches for reversing established osteoporosis.
Kimmel DB; Slovik DM; Lane NE
Rheum Dis Clin North Am; 1994 Aug; 20(3):735-58. PubMed ID: 7984787
[TBL] [Abstract][Full Text] [Related]
5. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
Compston JE
Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
[TBL] [Abstract][Full Text] [Related]
6. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
7. A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level.
Wang Y; Qin QH; Kalyanasundaram S
Mol Cell Biomech; 2009 Jun; 6(2):101-12. PubMed ID: 19496258
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone: a double-edged sword for bone metabolism.
Qin L; Raggatt LJ; Partridge NC
Trends Endocrinol Metab; 2004 Mar; 15(2):60-5. PubMed ID: 15036251
[TBL] [Abstract][Full Text] [Related]
9. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
Seeman E
Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
[TBL] [Abstract][Full Text] [Related]
10. [Parathyroid hormone for osteroporsis: why and who to treat?].
Ferrari S; Rizzoli R
Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450
[TBL] [Abstract][Full Text] [Related]
11. [Increase in bone mineral density and its effect on fracture risk].
Sone T
Clin Calcium; 2005 Apr; 15(4):625-9. PubMed ID: 15802775
[TBL] [Abstract][Full Text] [Related]
12. What's new with PTH in osteoporosis: where are we and where are we headed?
Rosen CJ
Trends Endocrinol Metab; 2004 Jul; 15(5):229-33. PubMed ID: 15223053
[TBL] [Abstract][Full Text] [Related]
13. Influence of the parathyroid glands on bone metabolism.
Malluche HH; Koszewski N; Monier-Faugere MC; Williams JP; Mawad H
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():23-33. PubMed ID: 16884395
[TBL] [Abstract][Full Text] [Related]
14. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
Takeuchi Y
Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of osteoporosis with parathyroid hormone].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
[TBL] [Abstract][Full Text] [Related]
16. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
Riggs BL; Parfitt AM
J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone as an anabolic therapy for women and men.
Bilezikian JP; Rubin MR; Finkelstein JS
J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201
[TBL] [Abstract][Full Text] [Related]
18. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis.
Bonnet N; Pierroz DD; Ferrari SL
J Musculoskelet Neuronal Interact; 2008; 8(2):94-104. PubMed ID: 18622078
[TBL] [Abstract][Full Text] [Related]
19. The cellular and clinical parameters of anabolic therapy for osteoporosis.
Rosen CJ
Crit Rev Eukaryot Gene Expr; 2003; 13(1):25-38. PubMed ID: 12839095
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone.
Goltzman D
Arch Biochem Biophys; 2008 May; 473(2):218-24. PubMed ID: 18358824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
